Pages that link to "Q33990928"
Jump to navigation
Jump to search
The following pages link to Phase II study of sorafenib in combination with docetaxel and cisplatin in the treatment of metastatic or advanced gastric and gastroesophageal junction adenocarcinoma: ECOG 5203. (Q33990928):
Displaying 50 items.
- Molecular-targeted therapy for advanced gastric cancer (Q24187006) (← links)
- Critical appraisal of trastuzumab in treatment of advanced stomach cancer (Q24604411) (← links)
- Molecular-targeted first-line therapy for advanced gastric cancer (Q26471049) (← links)
- New advances in targeted gastric cancer treatment (Q26738548) (← links)
- Current and emerging therapies in unresectable and recurrent gastric cancer (Q26745453) (← links)
- Recent updates of precision therapy for gastric cancer: Towards optimal tailored management (Q26746246) (← links)
- Targeted therapy for advanced gastric cancer: A review of current status and future prospects (Q26774138) (← links)
- Gastric cancer: The times they are a-changin' (Q26776195) (← links)
- Clinical utility of ramucirumab in advanced gastric cancer (Q26785665) (← links)
- Molecular classification of gastric cancer: Towards a pathway-driven targeted therapy (Q26798420) (← links)
- Critical evaluation of ramucirumab in the treatment of advanced gastric and gastroesophageal cancers (Q26801289) (← links)
- Advances in targeted therapies and new promising targets in esophageal cancer (Q26825957) (← links)
- Small molecule R1498 as a well-tolerated and orally active kinase inhibitor for hepatocellular carcinoma and gastric cancer treatment via targeting angiogenesis and mitosis pathways (Q27317155) (← links)
- Molecular targeted therapy for the treatment of gastric cancer (Q28072433) (← links)
- Efficacy and safety of angiogenesis inhibitors in advanced gastric cancer: a systematic review and meta-analysis (Q28079362) (← links)
- Sunitinib combined with pemetrexed and carboplatin in patients with advanced solid malignancies--results of a phase I dose-escalation study (Q33409913) (← links)
- Multicenter phase II study of oxaliplatin and sorafenib in advanced gastric adenocarcinoma after failure of cisplatin and fluoropyrimidine treatment. A GEMCAD study (Q33410627) (← links)
- Prospective phase II trial of pazopanib plus CapeOX (capecitabine and oxaliplatin) in previously untreated patients with advanced gastric cancer (Q33430940) (← links)
- A unified model of the hierarchical and stochastic theories of gastric cancer (Q33577624) (← links)
- The design and discovery of water soluble 4-substituted-2,6-dimethylfuro[2,3-d]pyrimidines as multitargeted receptor tyrosine kinase inhibitors and microtubule targeting antitumor agents (Q33872751) (← links)
- Targeted inhibition of VEGF receptor 2: an update on ramucirumab (Q34040956) (← links)
- Targeted therapies for gastric cancer: current status (Q34205672) (← links)
- Treatment options in patients with metastatic gastric cancer: current status and future perspectives (Q34661367) (← links)
- Docetaxel, cisplatin and fluorouracil (DCF) regimen compared with non-taxane-containing palliative chemotherapy for gastric carcinoma: a systematic review and meta-analysis (Q34672942) (← links)
- Current status of novel agents in advanced gastroesophageal adenocarcinoma (Q34962039) (← links)
- Targeting metastatic upper gastrointestinal adenocarcinomas (Q35000785) (← links)
- Phase I study of combination chemotherapy using sorafenib and transcatheter arterial infusion with cisplatin for advanced hepatocellular carcinoma (Q35051975) (← links)
- Refining docetaxel-containing therapy for gastric cancer. (Q35445166) (← links)
- Targeting angiogenesis in esophagogastric adenocarcinoma (Q35584958) (← links)
- Antiangiogenic agents in advanced gastrointestinal malignancies: past, present and a novel future (Q35640101) (← links)
- MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib (Q35666332) (← links)
- Phase II Trial of Sorafenib in Patients with Chemotherapy Refractory Metastatic Esophageal and Gastroesophageal (GE) Junction Cancer (Q35746639) (← links)
- Phase I dose-finding study of sorafenib with FOLFOX4 as first-line treatment in patients with unresectable locally advanced or metastatic gastric cancer (Q35812808) (← links)
- Targeted therapy in the management of advanced gastric cancer: are we making progress in the era of personalized medicine? (Q35863874) (← links)
- Cyclooxygenase isoenzyme-2 and vascular endothelial growth factor are associated with poor prognosis in esophageal adenocarcinoma (Q35884306) (← links)
- Inhibiting oncogenic signaling by sorafenib activates PUMA via GSK3β and NF-κB to suppress tumor cell growth (Q35928707) (← links)
- Targeted therapy for esophagogastric cancers: a review (Q36039645) (← links)
- Inhibition of β-catenin and STAT3 with a curcumin analog suppresses gastric carcinogenesis in vivo (Q36065487) (← links)
- Inefficiencies and Patient Burdens in the Development of the Targeted Cancer Drug Sorafenib: A Systematic Review (Q36270115) (← links)
- Targeted therapy in gastroesophageal cancers: past, present and future (Q36294579) (← links)
- Molecular targeted therapy for advanced gastric cancer (Q36705689) (← links)
- New and emerging combination therapies for esophageal cancer (Q36996728) (← links)
- Linifanib (ABT-869) Potentiates the Efficacy of Chemotherapeutic Agents through the Suppression of Receptor Tyrosine Kinase-Mediated AKT/mTOR Signaling Pathways in Gastric Cancer. (Q37076592) (← links)
- Transarterial chemoembolization combined with sorafenib for the treatment of hepatocellular carcinoma with hepatic vein tumor thrombus (Q37103489) (← links)
- Sorafenib plus hepatic arterial infusion chemotherapy with cisplatin versus sorafenib for advanced hepatocellular carcinoma: randomized phase II trial (Q37387978) (← links)
- Gastric cancer in the era of molecularly targeted agents: current drug development strategies (Q37442676) (← links)
- Developments in treatment of esophageal/gastric cancer (Q37461022) (← links)
- Targeted therapy in gastrointestinal malignancies (Q37702506) (← links)
- Targeted therapies for metastatic esophagogastric cancer (Q37836513) (← links)
- Angiogenesis-related molecular targets in esophageal cancer (Q37858534) (← links)